Human induced pluripotent stem cells (iPSCs) bring human biology into pre-clinical aspects of drug discovery. iPSC-derived cardiomyocytes have emerged as useful tools for detecting and predicting cardiotoxicity and proarrhythmia. The relevant biology of these cardiomyocytes provides a holistic reagent for testing numerous aspects of structural and functional biology, including on- and off-target toxicities. Syncytial hiPSC-derived cardiomyocytes exhibit highly-regular spontaneous beating with low sample-to-sample variation, which makes them adaptable to real-time functional screening in label-free multiwell platforms and facilitates studies of toxicity mechanisms ranging in time course from minutes to weeks. This webinar brings together speakers from Cellular Dynamics International (CDI) and Genentech to provide an overview of the technology and its implementation, respectively.
Attendees will learn:
- The functional human cardiac biology that iPSC-cardiomyocytes bring to the drug discovery arena.
- Strategies and instrumentation with which iPSC-derived cardiomyocytes are used in hypothesis-driven investigative toxicology studies at Genentech.
- New functional data on iCell Cardiomyocytes², the newest iteration of iCell Cardiomyocytes from CDI.
Note: The time shown is Pacific Time